Placebo News and Research

RSS

Researchers investigate CBD's effect on scan-related anxiety in breast cancer patients

The findings showed that CBD did not significantly change scan-related anxiety when compared to a placebo, but researchers did find that CBD was safe and resulted in significantly lower overall anxiety levels.

16 Dec 2024

Revolutionizing MASLD treatment with GLP-1 receptor agonists

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic dysfunction-associated steatotic liver disease.

16 Dec 2024

ZEST trial fails to meet enrollment goals for ctDNA testing in breast cancer

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for ctDNA, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Long-CoV-III-21 trial shows positive results for bovhyaluronidase azoximer in post-COVID pulmonary sequelae

Petrovax announced today the positive results from "Long-CoV-III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19.

12 Dec 2024

Novel treatment for inflammatory skin conditions could be on the horizon

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study published today in Science Translational Medicine.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

Toxic chemical exposure in early life linked to behavioral problems in rats

Early life exposure to a class of endocrine-disrupting chemicals (EDCs) called polychlorinated biphenyls (PCBs) may lead to behavioral problems in rats, according to a new animal study published in the Journal of the Endocrine Society.

10 Dec 2024

Filgotinib offers new promise for managing Crohn’s disease

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's disease, achieving clinical and endoscopic remission in phase 3 trials. The findings highlight its potential as a novel therapeutic option for difficult-to-treat patients.

8 Dec 2024

Researchers discover new receptor in pain signaling pathway

Researchers at the NYU Pain Research Center have found a new receptor for nerve growth factor that plays an important role in pain signaling, even though it does not signal on its own, according to a study published in the Journal of Clinical Investigation.

6 Dec 2024

Psilocybin helps reduce depression in clinicians amid COVID-19 crisis

Psilocybin-assisted psychotherapy resulted in significant reductions in depression among clinicians who provided front-line COVID-19 care in 2020 and 2021.

5 Dec 2024

Dupilumab improves symptoms of atopic dermatitis in children with co-existing conditions

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or not they have another inflammatory condition, such as asthma, allergic rhinitis or food allergies.

5 Dec 2024

Creatine and resistance workouts combat sarcopenia

Combining creatine supplementation with resistance training boosts muscle strength, lean mass, and cognitive health in older adults, offering a safe and effective strategy against sarcopenia.

4 Dec 2024

L-arginine shows potential in treating spinocerebellar ataxia type 6

A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a randomized, double-blind trial on the efficacy and safety of L-arginine in treating Spinocerebellar ataxia type 6 (SCA6).

3 Dec 2024

How carrageenan affects insulin resistance

A randomized controlled trial found that carrageenan, a common food additive, may cause subclinical inflammation and insulin resistance in overweight individuals, mediated by gut permeability and inflammation. Effects were linked to BMI but not observed in non-overweight participants during short-term exposure.

3 Dec 2024